India, Oct. 29 -- Eli Lilly and Company (LLY) reported higher third-quarter 2026 profit and revenue, driven primarily by strong demand for Mounjaro and Zepbound.
The company raised its full-year revenue outlook while lowering its adjusted earnings guidance to reflect acquisition-related research and development charges.
For the quarter ended September 30, 2026, Lilly reported net income of $6.451 billion, or $7.22 per share, compared with $5.583 billion, or $6.21 per share, in the year-ago quarter. Revenue increased 39% to $24.397 billion from $17.601 billion.
On a non-GAAP basis, net income rose to $6.679 billion, or $7.48 per share, from $6.312 billion, or $7.02 per share, a year earlier.
Reported and adjusted earnings per share inclu...